"Elite" HIV wife may hold secret to AIDS vaccine

WASHINGTON Tue Aug 12, 2008 5:02pm EDT

A volunteer suffering from HIV/AIDS makes AIDS symbols with red ribbons during a vaccination programme organised by a non-government organisation 'Sngobadho' (Together) at their office on the outskirts of the northeastern Indian city of Siliguri August 5, 2008. REUTERS/Rupak De Chowdhuri

A volunteer suffering from HIV/AIDS makes AIDS symbols with red ribbons during a vaccination programme organised by a non-government organisation 'Sngobadho' (Together) at their office on the outskirts of the northeastern Indian city of Siliguri August 5, 2008.

Credit: Reuters/Rupak De Chowdhuri

Related Topics

WASHINGTON (Reuters) - A woman who has never shown symptoms of infection with the AIDS virus may hold the secret to defeating the virus, U.S. researchers said on Tuesday.

Infected at least 10 years ago by her husband, the woman is able somehow to naturally control the deadly and incurable virus -- even though her husband must take cocktails of strong HIV drugs to control his.

She is a so-called "elite suppressor," and studies of her immune cells have begun to offer clues to how her body does it, the team at Johns Hopkins University in Baltimore said.

"This is the best evidence to date that elite suppressors can have fully pathogenic virus," said Dr. Joel Blankson, who led the study.

"The feeling was initially that they had defective virus," Blankson added in a telephone interview.

But the couple has been monogamous for at least 17 years, Blankson said, and tests show they are infected with the same strain of virus. What is different is the immune system of the wife, who cannot be named for privacy reasons.

"That's a good sign in terms of developing a therapeutic vaccine," Blankson said. Such a vaccine would not prevent infection but might be used to treat patients.

The AIDS virus infects at least 33 million people globally and more than a million in the United States. It has killed 25 million people since it was identified in the early 1980s.

New figures show 56,000 people are infected every year in the United states, mostly gay and bisexual men but also injecting drug users and their sexual partners, both male and female, as well as newborns and recipients of contaminated blood transfusions.

STALLING REPLICATION

Both the man and the woman, who are from Baltimore, were diagnosed 10 years ago, Blankson said. The husband is a former injecting drug user.

Tests showed that immune cells known as CD8 T-cells from the wife stalled HIV replication by as much as 90 percent, while the husband's T-cells stopped it by only 30 percent, Blankson's team reported in the Journal of Virology.

Her virus has also mutated in apparent response to this immune attack, becoming weaker, while her husband's virus has remained strong.

"Elite suppression offers clues to vaccine researchers on many fronts: how CD8 killer T-cells can attack HIV and how a stronger immune response can force HIV into a permanent defensive state," Blankson said.

"We are trying to figure out exactly how the T-cells work in her to inhibit viral replication," he added. "We are just trying to see what kind of cytokines they make."

Cytokines are immune system signaling proteins. One thing the researchers have noticed is that while the husband's T-cells make just one, called gamma interferon, hers made both that one and another called TNF, or tumor necrosis factor.

That cannot be the whole story, though, because AIDS researchers have tried using such immune system proteins in patients and they did not work well.

And her immune cells seem to make the response only when they encounter the virus.

Another clue: the woman may have unusual activity in her human leukocyte antigen system, or HLA, Blankson said. This important component of the immune system helps recognize antigens -- protein identifiers -- of enemies such as bacteria and viruses.

(Editing by Will Dunham and Philip Barbara)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.